Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Mar 22;8(11):2622–2634. doi: 10.1182/bloodadvances.2024012585

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Figure 2. — Daratumumab treatment reduced the abundance of B cells and affected subset distributions of T cells. PBMCs from 2 patients with wAIHA at different time points: baseline (Pre), during treatment (Mid), immediately after treatment cessation (EOT), 6 weeks after the last cycle (6 weeks), and 3 months after end of treatment (Post) were analyzed by flow cytometry, either right after thawing or after a 2- to 5-day culture-cell stimulation by αCD3/αCD28 antibodies. (A) Frequency and subset distribution of B cells over the course of daratumumab treatment. (B) Analysis of CD3⁺ and T_reg frequency, CD4⁺: CD8⁺ ratio, CD4⁺subset distribution and CD38 expression. (C) Hemoglobin (g/dL) levels of patients over course of treatment. CM, central memory; EM, effector memory; EMRA, effector memory RA⁺.